Johnson & Johnson says its ketamine-based drug can treat depression
Johnson & Johnson said on Monday that it submitted an application to the U.S. Food and Drug Administration (FDA) to expand the approved used of its ketamine-based drug Spravato to be used as a standalone alone therapy for treatment resistant depressionRead more…
Johnson & Johnson said on Monday that it submitted an application to the U.S. Food and Drug Administration (FDA) to expand the approved used of its ketamine-based drug Spravato to be used as a standalone alone therapy for treatment resistant depressionRead more…
Read More
About Author
